This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Patent and Trademark Office has proposed a new rule designed to stem the use of so-called patent thickets , which are wielded by pharmaceuticalcompanies to delay the arrival of lower-cost genericmedicines in the marketplace. In a bid to prevent the patent system from being abused, the U.S.
The Federal Trade Commission warned pharmaceuticalcompanies they could face legal action if they improperly list patents for brand-name medicines in a Food and Drug Administration registry, the latest effort by the federal government to scrutinize patent moves by drugmakers.
government to remove the key negotiator working on a free trade agreement with the Indian government because of his previous ties to a major pharmaceuticalcompany. More than 200 civil society and patient advocacy groups are urging the U.K. Now, the groups are upset that the involvement of Harjinder Kang, the U.K.
The Indian pharmaceutical sector is loaded with talent and has made great strides in genericmedicine development. However, massive R&D expenditure is necessary to drive the next generation of discoveries.
Britain is pushing for patent changes that could increase the cost of Indian generic drugs, diverting more of the NHS budget to big pharma India is known as the “ pharmacy of the world ”, supplying vital genericmedicines at low prices to health services including the NHS. They spend billions on research and recoup billions.
During this time, the role and responsibility of generics suppliers and manufacturers has been brought into stark perspective as one of the leading contributors in this industry-wide effort. The pandemic has further highlighted how research is not strictly limited to large, “innovator” pharmaceuticalcompanies.
Krishna Sarma, Managing Partner, Corporate Law Group , said, “The entanglement of Registered Medical Practitioners (RMPs) in third-party activities involving pharmaceuticalcompanies, coupled with the haze surrounding genericmedicines, beckons for clarity.
In a bid to resolve both physical and financial restrictions inhibiting equitable access to quality medicines, the Jan Aushadhi scheme was launched in 2008 and envisaged the setting up of dedicated Janaushadhi Kendras to provide quality genericmedicines at capped prices for the general public.
This left pharmaceuticalcompanies in Europe with no European API supply source, and only a few suppliers in Asia. A recent example was the sudden shortage of the API tamoxifen, used in a key breast cancer therapy, as the only European API manufacturer halted production because it had become uneconomical.
As the world’s leading supplier of generic drugs, India’s pharmaceutical industry has become a ray of hope for millions as it ensures quality-assured and cost-effective treatments reach those who need them the most.
Medicine indication extensions recommended by the CHMP The committee recommended extensions of indications for six EU-approved medicines, including: CARVYKTI ® ▼ (ciltacabtagene autoleucel; cilta-cel)* , Keytruda and Reblozyl*. These products were designated as an orphan medicine during their development.
It is a new type of medicine that works by stimulating a pair of muscarinic receptors in the brain, that, in turn, control the release of a brain chemical called acetylcholine. Current antipsychotics, which include genericmedicines and branded products, mostly regulate mood by blocking dopamine receptors.
As the world’s leading supplier of generic drugs, India’s pharmaceutical industry has become a ray of hope for millions as it ensures quality-assured and cost-effective treatments reach those who need them the most. Such partnerships are particularly valuable in addressing the healthcare needs of low- and middle-income countries.
The CJEU stressed that identical medicinal products are not those that are only therapeutically equivalent (as generics are to reference products), but they should be identical in all respects. He has been advising pharmaceuticalcompanies and healthcare providers for a number of years.
Within pharma and healthcare, where greater representation has been proven to lead to better health outcomes for all patients and the pharmaceuticalcompanies developing medicines, change is also happening. As a Non-Clinical Assessor at MHRA he assessed non-clinical data packages for new and genericmedicines.
This economic change impacts employment, income, industrial production, and more, and the pharmaceutical industry will not be exempt. While larger, more established pharmaceuticalcompanies may have the infrastructure and financial cushion to fall back on, SMEs need to tread carefully through these economic challenges.
The US imports a substantial volume of APIs and finished medicines, many of which are essential for patient care, meaning these tariffs could have far-reaching implications. 1 Here, we explore the potential impact of tariffs on pharmaceutical supply chains, pricing, investment and industry strategy.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content